In a comparative experiment conducted by Tahara et al. [48] on a T2DM mouse, the positive effects of six SGLT2-Is (luseogliflozin, ipragliflozin, tofogliflozin, empagliflozin, canagliflozin, and dapagliflozin) were compared, and it was noted that all six drugs were shown to improve endothelial dysfunction, which is a class effect of these agents. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.